Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Brummer & Partners in connection with its investment in Saltside Technologies AB
Mandate

Vinge advises Brummer & Partners in connection with its investment in Saltside Technologies AB

January 29, 2015

Vinge advises Frontier PE (Cayman) L.P., a fond managed by Brummer & Partners, in connection with its investment in Saltside Technologies AB together with Kinnevik and Hillhouse Capital. Saltside Technologies AB operates the leading online horizontal classifieds platforms in three frontier markets through Bikroy (Bangladesh), Ikman (Sri Lanka) and Tonaton (Ghana). All three platforms are market leaders in terms of user base, engagement and monetization. The headquarters are located in Dubai and the group has over 200 employees to date. Frontier PE (Cayman) L.P. is a private equity fund based in Bangladesh and managed by Brummer & Partners, a leading European manager of hedge funds. Brummer & Partners manages 125 billion SEK on behalf of private persons, corporations and institutional investors.

The Vinge team advising Frontier PE (Cayman) L.P. includes partners Christina Kokko and Johan Larsson together with associates Maria Dahlin, Karin Virding and Nicklas Thorgerzon.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025